Literature DB >> 10424408

Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.

K M Ignatoski1, S P Ethier.   

Abstract

Our laboratory has developed twelve human breast cancer cell lines from primary and metastatic sites. In this report we demonstrate that eight of eight breast cancer cell lines examined exhibit constitutively tyrosine phosphorylated and enzymatically active endogenous pp125fak when grown in monolayer. The activation status of pp125fak in breast cancer cells in monolayer is significantly elevated over that exhibited by normal mammary epithelial cells cultured under the same conditions. Constitutive activation of pp125fak is the only characteristic so far studied that all of these breast cancer cell lines have in common. In contrast to HBC cells, tyrosine phosphorylation of pp125fak in HME cells was low or absent in monolayer culture but was induced to high levels by culturing the cells in Matrigel. Thus tyrosine phosphorylation and activation of pp125fak is a regulated process in normal mammary epithelial cells, but is constitutive in breast cancer cells. Finally, analysis of the ability of normal human mammary epithelial cells and breast cancer cell lines to grow under anchorage-independent conditions indicated that normal human mammary epithelial cells rapidly and uniformly lost viability when not substrate-attached, whereas all of the breast cancer cell lines survived for a 3-week culture period. Furthermore, a subset of the breast cancer cell lines grew to form large colonies under anchorage-independent conditions. Interestingly, pp125fak activation decreased dramatically in HBC cells cultured for two weeks in suspension, suggesting that activation of this kinase is not necessary for long-term growth under anchorage-independent conditions. These results suggest that constitutive activation of pp125fak results in preferential survival of human breast cancer cells under anchorage-independent conditions but that activation of pp125fak is not the sole mediator of anchorage-independent colony formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424408     DOI: 10.1023/a:1006135331912

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells.

Authors:  V N Sumantran; D S Lee; K M Woods Ignatoski; S P Ethier; M S Wicha
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Ferroportin and iron regulation in breast cancer progression and prognosis.

Authors:  Zandra K Pinnix; Lance D Miller; Wei Wang; Ralph D'Agostino; Tim Kute; Mark C Willingham; Heather Hatcher; Lia Tesfay; Guangchao Sui; Xiumin Di; Suzy V Torti; Frank M Torti
Journal:  Sci Transl Med       Date:  2010-08-04       Impact factor: 17.956

3.  The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions.

Authors:  Tsukasa Shibue; Mary W Brooks; M Fatih Inan; Ferenc Reinhardt; Robert A Weinberg
Journal:  Cancer Discov       Date:  2012-05-18       Impact factor: 39.397

4.  USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers.

Authors:  Shiva Akhavantabasi; Hesna B Akman; Aysegul Sapmaz; Jennifer Keller; Elizabeth M Petty; Ayse E Erson
Journal:  Mamm Genome       Date:  2010-06-13       Impact factor: 2.957

5.  Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells.

Authors:  A E Erson; B L Niell; S K DeMers; J M Rouillard; S M Hanash; E M Petty
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

6.  RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

Authors:  Yifan Wang; John J Krais; Andrea J Bernhardy; Emmanuelle Nicolas; Kathy Q Cai; Maria I Harrell; Hyoung H Kim; Erin George; Elizabeth M Swisher; Fiona Simpkins; Neil Johnson
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

7.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

8.  Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.

Authors:  Stephanie Tseng-Rogenski; Jason Gee; Kathleen Woods Ignatoski; Lakshmi P Kunju; Amanda Bucheit; Hallie J Kintner; David Morris; Christopher Tallman; Joshua Evron; Christopher G Wood; H Barton Grossman; Cheryl T Lee; Monica Liebert
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression.

Authors:  Hicham Lahlou; Virginie Sanguin-Gendreau; Dongmei Zuo; Robert D Cardiff; Gordon W McLean; Margaret C Frame; William J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

10.  Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

Authors:  Lynda Mezil; Carole Berruyer-Pouyet; Olivier Cabaud; Emmanuelle Josselin; Sébastien Combes; Jean-Michel Brunel; Patrice Viens; Yves Collette; Daniel Birnbaum; Marc Lopez
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.